STOCK TITAN

Medtronic plc (MDT) Stock News

MDT NYSE

Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.

Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.

Rhea-AI Summary

Orchestra BioMed (Nasdaq: OBIO) will participate in the Piper Sandler 38th Annual Healthcare Conference in New York City on December 1–3, 2026.

Chairman and CEO David Hochman will join a fireside chat hosted by Piper Sandler analyst Matthew O’Brien on December 2 at 9:00 a.m. ET. Management will also hold one-on-one investor meetings. A live webcast will be accessible through the company’s Investor Relations website, with a replay available afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
Rhea-AI Summary

Medtronic (NYSE: MDT) received FDA clearance to expand its Hugo robotic-assisted surgery system into general surgery procedures in the United States. The expanded 510(k) clearance covers all upper abdominal general surgical procedures, including gallbladder removal, Roux-en-Y gastric bypass, ventral hernia repair and small bowel resection. It also covers lower abdominal inguinal hernia procedures and appendectomy, expanding U.S. use beyond urology.

Medtronic said global Hugo procedure growth is running at more than twice the robotic surgery market's growth, with procedure volume on track to surpass 50,000 by its fiscal year-end. Outside the United States, general surgery represents Hugo's highest procedure growth, surpassing urology and gynecology. The system is in clinical use at a growing number of U.S. hospitals and health systems.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Summary

Medtronic (MDT) plans to acquire privately held Contego Medical in a transaction valued at $380 million, with potential payments after acquisition. Medtronic expects completion in its fiscal third quarter, subject to customary closing conditions.

The acquisition would add the recently FDA-approved Neuroguard IEP Direct System for carotid artery treatment and Excipio devices for removing blood clots from peripheral vessels. In the prospective, multicenter PERFORMANCE III study, Neuroguard IEP Direct recorded zero strokes, neurological deaths, cranial nerve injuries or myocardial infarctions at 30 days.

Medtronic expects the acquisition to be minimally dilutive to adjusted earnings per share in FY27 and FY28, meaning a small reduction, and neutral to accretive thereafter. The planned deal builds on an exclusive U.S. distribution agreement with Contego first announced in January 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
Rhea-AI Summary

Orchestra BioMed (Nasdaq: OBIO) reported a third-quarter 2026 loss attributable to common stockholders of $19.6 million as pivotal trials advanced. Loss per share narrowed to $0.30 from $0.40 a year earlier, while revenue fell to $91,000 from $861,000.

The BACKBEAT trial completed enrollment with 349 patients randomized, exceeding its target. Primary endpoint results are planned for submission for presentation consideration at HRS 2027. Medtronic plans an FDA marketing application supplement after presentation, assuming positive results. The Virtue trial targets enrollment completion by the end of 2027.

A public offering closed November 9, 2026, issuing 17,250,000 shares at $5.00 and raising approximately $80.5 million net. Cash, cash equivalents and marketable securities totaled $101.9 million at September 30, excluding the offering. Orchestra projects these funds and offering proceeds will support operations through 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
-
Rhea-AI Summary

Imperative Care appointed former Medtronic executive Brett Wall and Stanford biodesign center co-founder Dr. Josh Makower to its board of directors.

Wall joins as an independent director. He most recently served as executive vice president and president of Medtronic’s neuroscience portfolio, following leadership roles at Micro Therapeutics, ev3 and Covidien.

Makower joins as the representative for Elevage Medical Technologies, replacing Dr. Evan Melrose. He is a senior advisor and board member at Elevage and director and co-founder of the Stanford Mussallem Center for Biodesign. Imperative Care also announced that Holly Sheffield has stepped down from its board after five years of service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
management
-
Rhea-AI Summary

Orchestra BioMed (Nasdaq: OBIO) priced an underwritten public offering of common stock expected to raise $75.0 million in gross proceeds. The offering comprises 15,000,000 shares at $5.00 per share, with closing expected on November 9, 2026, subject to customary closing conditions. Underwriters have a 30-day option to purchase up to 2,250,000 additional shares.

The company intends to use net proceeds alongside existing cash and cash equivalents to fund its AVIM Therapy program and BACKBEAT pivotal trial, its Virtue SAB program and Virtue Trial, and other product development, with the remainder for working capital and general corporate purposes. Expected gross proceeds exclude underwriting discounts, commissions and estimated offering expenses and assume no exercise of the option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.90%
Tags
Rhea-AI Summary

Orchestra BioMed (Nasdaq: OBIO) has commenced an underwritten public offering of common stock, with all shares offered by the company. It intends to grant underwriters a 30-day option to buy up to an additional 15% of the shares sold, at the public offering price less underwriting discounts and commissions.

The company plans to use net proceeds together with existing cash to fund its AVIM Therapy program and BACKBEAT pivotal trial, its Virtue SAB program and Virtue Trial, and other research and clinical development, with the remainder for working capital and general corporate purposes. Completion and terms remain subject to market and other conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.90%
Tags
-
Rhea-AI Summary

Medtronic (NYSE: MDT) will report its second-quarter fiscal 2027 financial results on November 24, 2026, before hosting a video webcast. The quarter ended October 30, 2026. The results release is scheduled for 5:45 a.m. Central Time, followed by the webcast at 6:30 a.m. Central Time. A replay and transcript of prepared remarks will be available on its investor relations website within 24 hours of the webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
earnings date
-
Rhea-AI Summary

Medtronic (NYSE: MDT) and the Michael J. Fox Foundation launched an educational initiative to help people with Parkinson's understand deep brain stimulation. The therapy uses a surgically implanted device to deliver electrical signals to brain areas that control movement.

Medtronic is the initiative's premier partner, while the Foundation retains editorial oversight. The partners aim to help patients and caregivers discuss treatment options with their care teams. Resources available at michaeljfox.org/dbs cover how the therapy works, potential benefits and risks, surgery preparation and life with a device. Deep brain stimulation is not appropriate for everyone and is used alongside medication.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.15%
Tags
partnership
Rhea-AI Summary

Medtronic (MDT) reported six-month blood pressure reductions in the SPYRAL AFFIRM post-approval study of its Symplicity Spyral renal denervation system. The procedure treats nerves near the kidneys. Office systolic blood pressure fell 18.2 mmHg from baseline; home and 24-hour ambulatory readings fell 9.4 and 9.7 mmHg, respectively. All three reductions were statistically significant, with no increase in blood pressure medications. Nearly nine out of 10 patients experienced clinical benefit, while the composite safety endpoint occurred in 2.1%.

The prospective, single-arm study compared six-month U.S. results with a prespecified performance goal. Medtronic also received FDA approval for a labeling update adding clinical evidence for certain patient groups; the indication remains unchanged.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none

FAQ

What is the current stock price of Medtronic (MDT)?

Medtronic (MDT) last closed at $100.61.

What is the market cap of Medtronic (MDT)?

The market cap of Medtronic (MDT) is approximately $128.7B.